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Abstract: Complete surgical resection of glioblastoma is difficult due to the invasive nature of
this primary brain tumor, for which the molecular mechanisms behind remain poorly understood.
The three human ELMO genes play key roles in cellular motility, and have been linked to metastasis
and poor prognosis in other cancer types. The aim of this study was to investigate methylation levels
of the ELMO genes and their correlation to clinical characteristics and outcome in patients diagnosed
with glioblastoma. To measure DNA methylation levels we designed pyrosequencing assays targeting
the promoter CpG island of each the ELMO genes. These were applied to diagnostic tumor specimens
from a well-characterized cohort of 121 patients who received standard treatment consisting of
surgery, radiation therapy, plus concomitant and adjuvant chemotherapy. The promoter methylation
levels of ELMO1 and ELMO2 were generally low, whereas ELMO3 methylation levels were high,
in the tumor biopsies. Thirteen, six, and 18 biopsies were defined as aberrantly methylated for ELMO1,
ELMO2, and ELMO3, respectively. There were no significant associations between the methylation
status of any of the ELMO gene promoter CpG islands and overall survival, progression-free
survival, and clinical characteristics of the patients including intracranial tumor location. Therefore,
the methylation status of the ELMO gene promoter CpG islands is unlikely to have prognostic value
in glioblastoma.
Keywords: glioblastoma; invasion; motility; clinical outcome; DNA methylation; ELMO1;
ELMO2; ELMO3
1. Introduction
Glioblastoma is the most common primary tumor of the central nervous system among adults [1].
Patients typically survive between 12 to 15 months following diagnosis, in spite of extensive treatment
with surgery, radiation, and chemotherapy [2,3]. Invasion of tumor cells into the surrounding brain
tissue makes complete surgical resection, as well as full radiation of all tumor cells difficult in
glioblastoma. This invasive capacity has been linked to fast recurrence of the tumors, which most
often manifest within 2 to 3 cm of the resection cavity [4]. The degree of invasiveness does not always
correlate with the grade of malignancy, as exemplified by frequent observations of extensive tumor cell
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infiltration into normal brain tissue in low-grade astrocytomas [5]. The molecular mechanisms behind
the aberrant cellular motility of glioma cells remain poorly understood. A better understanding of the
factors promoting the invasive nature of glioma cells may lead to identification of prognostic markers
and novel targets for treatment.
Recently, it has become apparent that engulfment and cell motility (ELMO) genes play central
roles in the dissemination and invasion of cancer cells [6–11]. In humans, the ELMO family
consists of three proteins, namely ELMO1, ELMO2, and ELMO3, which are involved in cytoskeleton
rearrangements during phagocytosis and cellular migration via the activation of Ras-related C3
botulinum toxin substrate (RAC) proteins [12–14]. The ELMO proteins lack a catalytic domain but
function as scaffolding proteins regulating the spatiotemporal localization and activity of Dedicator
Of Cytokinesis (DOCK) guanine exchange factors (GEFs), which are required to promote the active,
GTP-bound form of RAC proteins [15]. On the other hand, GTPase activating proteins (GAPs), such as
ARHGAP31 (CDGAP) may return RAC to its inactive, GDP-bound state [16,17]. The activation of
RAC proteins promotes the growth of actin filaments, which drive cell migration and invasion of
cancer cells [10,18,19] (Figure 1). In glioblastoma, ELMO1 has been shown to be specifically abundant
in invasive areas of the tumors and to be central for promoting cell migration and invasion via
activation of RAC1 [6,20,21]. On the contrary, less is known about the roles of ELMO2 and ELMO3
in glioblastoma.
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associated with variation in genes that are related to glioblastoma survival and treatment efficacy,
including global hypermethylation resulting from isocitrate dehydrogenase (IDH) mutation [31,32] and
inverted correlation between promoter methylation and protein expression of O6-methylguanine-DNA
methyltransferase (MGMT) [33]. However, the methylation levels of the ELMO gene promoter CpG
islands have not previously been reported in this disease.
We hypothesized that methylation levels of the ELMO promoter CpG islands in glioblastoma may
influence the motility of glioma cells and, therefore, potentially have prognostic value. To investigate
this, we developed sensitive and quantitatively accurate assays for DNA methylation detection
based on pyrosequencing and studied a well-characterized cohort of 121 patients diagnosed with
glioblastoma. Methylation levels of the individual ELMO promoter CpG islands were examined for
correlation with clinical characteristics of the patients as well as progression-free survival (PFS) and
overall survival (OS). In addition, we analyzed publically available methylation- and expression data
for the ELMO genes.
2. Results
2.1. Methylation Levels of the ELMO Promoter CpG Islands in Glioblastoma
The pyrosequencing assays for ELMO1, ELMO2, and ELMO3 interrogates three, seven and four
individual CpG sites, respectively, within the promoter CpG islands, which include the first exon for
all of them (Figure 2).
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Figure 2. Overview of the CpG sites analyzed for each of the ELMO promoters in this and previous
studies. The displayed regions each corresponds to 600 bp. Vertical bars represent CpG sites. CpG sites,
which have Illumina CpG loci IDs (cg#) are indicated. The orange horizontal lines represent exons.
Black bars underline the CpG sites studied here. Red bars underline the CpG sites studied in [25]. The
green bar underlines the CpG sites studied in [34]. The blue bar underlines the CpG sites studied in [8].
(A) ELMO1; (B) ELMO2; (C) ELMO3.
Among 121 included glioblastoma patients, successful pyrosequencing results were obtained from
113, 104, and 119 of the patient samples for ELMO1, ELMO2, and ELMO3, respectively. The methylation
levels of the three promoter CpG islands for each of the samples can be found in the supplementary
materials, while representative results for each of the genes are shown in Figure 3.
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We further investigated if patients with an aberrantly methylated sample for one of the ELMO 
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significantly correlated with ELMO3 methylation levels (Figure 5). 
Figure 3. Representative DNA methylation data acquired using pyrosequencing. (A) ELMO1;
(B) ELMO2; (C) ELMO3.
The mean ELMO1, ELMO2, and ELMO3 methylation levels in the tumor biopsies were 6.8% (SD
3.9), 3.3% (SD 2.6), and 80.6% (SD 13.0), respectively. Thirteen and six samples had methylation levels
greater than one SD above the cohort mean for ELMO1 and ELMO2, respectively, and were defined
as hypermethylated. Eighteen samples had methylation levels greater than one SD below the cohort
mean for ELMO3 and were defined as hypomethylated (Figure 4).
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 14 
 
 
Figure 3. Representative DNA methylation data acquired using pyrosequencing. (A) ELMO1; (B) 
ELMO2; (C) ELMO3. 
The ean EL 1, EL 2, and EL 3 ethylation level  in the tumor biopsies wer  6.8% (SD 
3.9), 3.3  (SD 2.6), and 80.6  (SD 13.0), respectively. Thirteen and six samples had m thylation levels 
greater than one SD above the cohort mean for EL O1 and ELMO2, respectively, and were defined 
as hypermethylated. Eighteen samples had methylation levels greater than one SD below the cohort 
mean for ELMO3 and were defined as hypomethylated (Figure 4). 
 
Figure 4. DNA methylation levels in the glioblastoma samples. Hypermethylated cases for ELMO1 
and ELMO2 and hypomethylated cases for ELMO3 are indicated in orange color. The green bars 
indicate m an methylation l v ls f r each gene promot  CpG island. 
We further investigated if patients wi  an aberrantly methylated sample for one of th  ELMO 
gene promoter CpG islands were more likely to have aberrant methylation for one of the other CpG 
islands. This was not the case as only a weak correlation was found between ELMO1- and ELMO2 
methylation levels. On the other hand, the methylation levels of none of these genes were 
significantly correlated with ELMO3 methylation levels (Figure 5). 
Figure 4. DNA methylation levels in the glioblastoma samples. Hypermethylated cases for ELMO1 and
ELMO2 and hypomethylated cases for ELMO3 are indicated in orange color. The green bars indicate
mean methylation levels for each gene promoter CpG island.
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methylation levels. On the other hand, the methylation levels of none of these genes were significantly
correlated with ELMO3 methylation levels (Figure 5).
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2.2. ethylation Levels of the EL O Gene Promoters in Normal Tis ues
Methylation levels of the ELMO gene promoter CpG islands in normal tissues were investigated by
consulting publically available data sets using the R2: G nomics Analysis a d Visualization Platform
(http://r2.amc.nl). The ELMO1 (cg15947096) and ELMO2 (cg09287717) promoter CpG islands were
found to b methylated at low levels (average (a g.) 11% nd avg. 4%, respecti ely) in all ten different
huma tissues that were analyzed by Slieker nd co-workers [35]. Like ise, the ELMO2 promoter
CpG island (cg09287717) w s found to be methylated at l w lev ls (avg. 2%) in all 17 different human
tissues, including medulla oblongata and ischiatic nerve, as analyzed by Lokk nd co-workers [36].
None f the CpG sites that we analyzed in the ELMO3 promoter CpG Island using pyrosequencing
were includ d in these data sets. Howev r, ne rby CpG sit s (cg25341653 and cg19514469) were
methylated at relatively high levels ( vg. 63% and a g. 52%, respectively) in all of the tissu s analyzed
by Slieker and co-workers [35], and in all tissues analyzed by Lokk and co-workers (avg. 65% and avg.
48%, r spectively) [36]. Altogether, these analyses indicate at low level methylat on of the ELMO1
and ELMO2 promoter CpG isl s, and high level methylat on of the ELMO3 promoter CpG Island are
normal, whereas hypermethylation of ELMO1 and ELMO2 and hypomethylation of ELMO3 are likely
to be associated with a malign nt phenotype. In upport of this, using the R2: Genomics Analysis and
Visualization Platform, we al o found th t ELMO1 and ELMO2 a e expressed at high levels, whereas
ELMO3 is express d at low levels, in normal brain tissues analyz d by Berchto d and co-workers [37].
2.3. DNA Methylation Status of the ELMO Promoter CpG Islands According to Patient Characteristics
The baseline clinical characteristics of the glioblastoma patients as a function of the methylation
status of the respective ELMO promoter CpG islands are shown i Table 1. There was no significant
association between the methylation status of any of the ELMO promoter CpG islands and any of
the exami ed clinical characteristics, including age, gender, WHO performance status, diagnosis,
use of corticosteroids t treatment start, multifocal disease, tumor br in loc tion, site f relapse
tumor, or MGMT promoter methylation. However, tendencies were observed that patients with an
ELMO1 hypermethylated tumor were unmethylated at the MGMT promoter (p = 0.053), and likewise
t at pati nts with an ELMO3 hypomethylated tumor were unmethylated at the MGMT promoter
( = 0.137).
2.4. Survival Analyses According to DNA Methylation Status of the ELMO Genes
Univariate analysis of ELMO CpG island methylation status with survival endpoints found no
statistically significant differences in OS or PFS of the patients according to the methylation status of
any of the ELMO promoter CpG islands (Table 2). However, a tendency was observed for a shorter
PFS in patients with an ELMO3 hypomethylated tumor (Hazard ratio; 1.48, 95% confidence interval;
0.89–2.47, p = 0.129).
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Table 1. DNA Methylation Status of the ELMO Genes According to Patient Characteristics.
Clinical Variable All(n = 121)
ELMO1
Hypermet
(n = 13)
ELMO1
Normal Met
(n = 99)
p-Value
ELMO2
Hypermet
(n = 6)
ELMO2
Normal Met
(n = 97)
p-Value
ELMO3
Hypomet
(n = 18)
ELMO3
Normal Met
(n = 101)
p-Value
Age (years), median (range) 59.0(23–74) 58.0 (40–67) 59.0 (23–74) 0.898 56.0 (46–71) 60 (23–74) 0.728 60.0 (23–74) 58.0 (31–72) 0.602
Gender, n (%)
Female 39 (32.2) 4 (30.8) 34 (34.3) 1.000 3 (50.0) 31 (32.0) 0.394 8 (44.4) 30 (29.7) 0.273
Male 82 (67.8) 9 (69.2) 65 (65.7) 3 (50.0) 66 (68.0) 10 (55.6) 71 (70.3)
WHO performance status,
n (%)
0 69 (57.0) 8 (61.5) 58 (61.7) 1.000 4 (66.7) 57 (62.0) 1.000 9 (52.9) 59 (61.5) 0.594
1–2 46 (38.1) 5 (38.5) 36 (38.3) 2 (33.3) 35 (38.0) 8 (47.1) 37 (38.5)
Missing 6 (4.9) 0 5 0 5 1 5
Diagnosis, n (%)
Primary Glioblastoma 116 (95.9) 13 (100.0) 94 (94.9) 1.000 6 (100.0) 92 (94.8) 1.000 18 (100.0) 96 (95.0) 1.000
Secondary Glioblastoma 5 (4.1) 0 (0.0) 5 (5.1) 0 (0.0) 5 (5.2) 0 5 (5.0)
Corticosteroid use, n (%)
Yes 86 (71.1) 10 (76.9) 71 (72.4) 1.000 5 (100.0) 66 (68.8) 0.318 12 (66.7) 73 (73.7) 0.570
No 33 (27.3) 3 (23.1) 27 (27.6) 0 (0.0) 30 (31.3) 6 (33.3) 26 (26.3)
Missing 2 (1.7) 0 1 1 1 0 2
Multifocal Disease, n (%)
Yes 8 (6.6) 0 (0.0) 7 (7.1) 1.000 1 (16.7) 7 (7.2) 0.392 2 (11.1) 5 (5.0) 0.286
No 113 (93.4) 13 (100.0) 92 (92.9) 5 (83.3) 90 (92.8) 16 (88.9) 96 (95.0)
Tumor brain location, n (%)
Frontal 26 (21.5) 1 (7.7) 23 (23.2) 0.292 3 (50.0) 22 (22.7) 0.152 5 (27.8) 19 (18.8) 0.358
Other 95 (78.5) 12 (92.3) 76 (76.8) 3 (50.0) 75 (77.3) 13 (72.2) 82 (81.2)
Site of relapse tumor, n (%)
Local in primary site 70 (57.9) 8 (80.0) 58 (84.1) 0.666 4 (100.0) 54 (83.1) 1.000 13 (86.7) 57 (85.1) 1.000
Distant from primary site 13 (10.7) 2 (20.0) 11 (15.9) 0 (0.0) 11 (16.9) 2 (13.3) 10 (14.9)
Missing 38 (31.4) 3 30 2 32 3 34
MGMT promoter
methylation, n (%)
Yes 38 (31.4) 1 (8.3) 35 (38.5) 0.053 2 (40.0) 31 (34.8) 1.000 2 (14.3) 34 (35.8) 0.137
No 73 (60.3) 11 (91.7) 56 (61.5) 3 (60.0) 58 (65.2) 12 (85.7) 61 (64.2)
Missing 10 (8.3) 1 8 1 8 4 6
Statistical tests: Mann-Whitney U test (Age); Fisher’s exact test (Gender, WHO performance status, Diagnosis, Corticosteroid use at start treatment, Multifocal disease, Tumor brain
location, Site of relapse tumor, MGMT promoter methylation). Abbreviations: met (methylation).
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Table 2. Survival analyses according to DNA methylation status of the ELMO genes.
Clinical
Endpoint
All
(n = 121)
ELMO1
Hypermet
(n = 13)
ELMO1
Normal Met
(n = 99)
HR (95% CI)
p-Value
ELMO2
Hypermet
(n = 6)
ELMO2
Normal Met
(n = 97)
HR (95% CI)
p-Value
ELMO3
Hypomet
(n = 18)
ELMO3
Normal Met
(n = 101)
HR (95% CI)
p-Value
OS (mo),
median (range) 14.0 (1–131) 14.0 (4–31) 14.0 (1–131)
1.12
(0.62–2.01)
p = 0.71
10.0 (1–27) 14.0 (1–131)
1.32
(0.57–3.03)
p = 0.530
12.0 (7–43) 14.0 (1–131)
1.16
(0.70–1.92)
p = 0.567
PFS (mo),
median (range) 6.0 (0–131) 7 (2–21) 7 (0–131)
1.03
(0.58–1.85)
p = 0.91
9.0 (1–16) 6.0 (0–131)
1.15
(0.50–2.64)
p = 0.75
4.0 (3–30) 7.0 (0–131)
1.48
(0.89–2.47)
p = 0.129
Statistical tests: Kaplan-Meier method for estimation of OS and PFS using the Cox proportional hazards model. Abbreviations: met (methylation); OS (overall survival); PFS (progression-free
survival); HR (Hazard Ratio); mo (months).
Int. J. Mol. Sci. 2018, 19, 679 8 of 13
3. Discussion
In glioblastoma, the poor outcome of patients has been linked to the invasive nature of the cancer.
The association of the ELMO genes to cancer cell migration primed us to profile the methylation
levels of all three human ELMO genes in a cohort of 121 glioblastoma patients, and examine if
aberrant methylation of the ELMO genes is correlated to patient clinical characteristics and survival.
The ability to assess methylation levels quantitatively is crucial for establishing specific assays for
clinical use [38–40]. Therefore, we used pyrosequencing, which is a quantitatively accurate method [41]
that is already in clinical use for assessment of MGMT methylation levels in glioblastoma. We found
that the methylation levels of ELMO1 and ELMO2 were generally low, whereas ELMO3 methylation
levels were high, in the glioblastoma samples. However, some patient samples were hypermethylated
for ELMO1 and ELMO2, and some patient samples were hypomethylated for ELMO3 (Figure 4).
This corresponds well with previous findings from other types of cancer, where promoter hyper- and
hypomethylation have been observed in a subset of cases for ELMO1 and ELMO3, respectively [8,25,34].
On the contrary, this study is, to our knowledge, the first to describe methylation of the ELMO2
promoter in cancer. In addition, we found that ELMO1 and ELMO2 are methylated at very low levels
across a large number of different non-cancerous human tissues, whereas as ELMO3 is normally
methylated at high levels. Therefore, it is likely that the observed hypermethylation in a subset of cases
for ELMO1 and ELMO2, and hypomethylation in a subset of cases for ELMO3, represent events that
are associated with the malignant phenotype. We have previously observed that the methylation level
of the ELMO3 promoter CpG Island is inversely correlated with expression of the gene [8], however,
such potential correlations have not been investigated for ELMO1 and ELMO2.
To assess whether the methylation levels of the ELMO genes have an impact on outcome
in glioblastoma we used cut-offs to separate the patients into two groups for each of the genes.
These cut-offs were defined as one standard deviation above the cohort mean for ELMO1 and
ELMO2 and as one standard deviation below the cohort mean for ELMO3 (Figure 4). We found
that this was more appropriate for the data of this study in comparison to the use of medians as
cut-offs, as this implied that the groups of high- and low methylation contained samples of very
similar methylation levels. In addition, we have previously successfully used one standard deviation
below the cohort mean as cut-off in a study of LINE-1 methylation levels in diffuse large B-cell
lymphoma [40], supporting use of this cut-off. Using these pre-defined cut-offs, we did not observe
any statistically significant correlations between ELMO methylation status and neither patient- and
tumor characteristics nor survival of the patients. This included the presence of multifocal disease and
a site for the recurrent tumor distant from the primary site. This argues against the ELMO variants
being a central driver of glioblastoma intracranial spread. Still, there was a tendency for patients
with a hypomethylated ELMO3 promoter to have shorter PFS. High expression of ELMO3 have been
linked with poor prognosis in lung cancer [42], head and neck squamous cell carcinoma [43], and
laryngeal cancer [44], and we have previously shown that methylation levels of the ELMO3 promoter
is inversely correlated with expression of the gene [8]. Thus, this could support that our data reflect
a worse therapeutic response for patients having a tumor with a hypomethylated ELMO3 promoter.
However, we also noted a tendency that hypomethylation of ELMO3 co-existed with an unmethylated
MGMT promoter. Since glioblastoma patients receiving Stupp’s regimen having an unmethylated
MGMT promoter present shorter PFS and OS [2,33], this may also explain the shorter PFS of patients
with ELMO3 hypomethylation.
In conclusion, we have characterized the methylation levels of several individual CpG sites in the
three human ELMO gene promoter CpG islands in a large well-characterized cohort of glioblastoma
patients. Aberrant methylation levels were only present in a small subset of patients and were not
associated with OS, PFS, or clinical characteristics of the patients. Therefore, the methylation status of
the ELMO genes is unlikely to have prognostic value in glioblastoma. However, we cannot exclude
that different results may be obtained if other CpG sites within the ELMO gene promoters are analyzed,
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and additional cohorts should be analyzed to firmly establish that the ELMO genes do not play a role
in the pathogenesis of glioblastoma.
4. Materials and Methods
4.1. Patient Samples
This retrospective study examined material from 121 patients diagnosed with glioblastoma (World
Health Organization (WHO) grade IV), according to the WHO 2000/2007 guidelines from 2005 to
2010. In addition to a diagnosis with glioblastoma, patient inclusion criteria were that tumor DNA
was available and that patients had received primary standard glioblastoma therapy according to the
Stupp regimen (concomitant radiation and temozolomide therapy followed by up to six courses of
adjuvant temozolomide therapy) at Rigshospitalet, Denmark. This patient material has previously
been used in a study investigating MGMT methylation patterns in glioblastoma [33] and the MGMT
data analyzed here is from this study.
For most patients, primary operation consisted of either partial resection (64 patients) or gross total
resection (53 patients), while three patients were biopsied only (data missing, n = 1). Median number of
adjuvant courses of temozolomide therapy was four, and best clinical response on Stupp treatment was
partial response for 16 patients, stable disease for 53 patients, and progressive disease for 47 patients
(data missing, n = 5). After progression on primary therapy, 51 of the 121 patients received reoperation
(data missing, n = 8), while 59 of the 121 patients received various types of palliative therapy (data
missing, n = 9), of which 53 received avastin combined with irinotecan. The median duration of
observation from the day patients first received radiation/temozolomide therapy to the project cutoff
day (2 February 2017) was 112 months (range, 73–142 months). At this time point, three patients were
still alive, of which two had not progressed on Stupp treatment. More patient characteristics are shown
in Table 1, while detailed descriptions of the treatments and patient evaluations have been described
elsewhere [45].
4.2. Ethics Statement
This study was performed according to the Declaration of Helsinki and Danish legislation.
Permissions were given from the Danish Data Protection Agency (2015-41-4118, 01. 09. 2015) and the
ethical committee for the Capital Region of Denmark (H-C-2008-095, 10. 10. 2008).
4.3. DNA Purification and Sodium Bisulfite Treatment
DNA was obtained from fresh frozen tumor tissue obtained from the primary diagnostic
glioblastoma surgery before exposure to radiation or chemotherapy treatment. Approximately 50 mg
homogenized tissue was used for extraction by employing standard Proteinase K-Phenol/Chloroform
extraction and sodium bisulfite conversion as described [33].
4.4. DNA Methylation Analyses Using Pyrosequencing
Pyrosequencing is a quantitatively accurate method for the analyses of DNA methylation at single
nucleotide resolution [39,46,47]. We designed and optimized novel pyrosequencing assays for the
promoter regions of ELMO1, ELMO2 and ELMO3, respectively, based on methylation independent
PCR (MIP) primers [48] (Figure 6). The PCR and sequencing primers were designed using the
PyroMark Assay Design 2.0 software (Qiagen, Hilden, Germany) and the sequences are listed in
Table 3. PCR was performed on the Gene PCR System 9700 (Applied Biosystems, Foster City, CA,
USA). The PyroMark PCR Master Mix (Qiagen) was used, according to the manufactures’ instructions,
with primer concentrations of 200 nM and 1 µL bisulfite converted DNA was used as template.
The cycling protocol started with 1 cycle of 95 ◦C for 10 min, followed by 45 cycles of 95 ◦C for 5 s,
58 ◦C for 10 s, 72 ◦C for 10 s. Samples were sequenced on the PyroMark Q24 (Qiagen) using the
PyroMark Gold Q24 reagents (Qiagen), according to the manufactures’ instructions. Methylated DNA
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(Chemicon, Millipore, Billerica, MA, USA), unmethylated DNA (Qiagen), 50% methylated DNA and no
template controls (NTCs) were included in all of the experiments. For each gene, the mean methylation
levels of the analyzed CpG sites were used in subsequent analyses. Hyper- and hypomethylation was
defined as a methylation level above or below the cohort mean methylation level plus or minus one
standard deviation, respectively. The cutoffs were 10.7, 5.9, and 67.6% for ELMO1, ELMO2, and ELMO3,
respectively. Data were only included in subsequent analyses if there was no warnings associated with
the analyses of methylation levels using the pyrosequencing software with default settings.
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arrows and sequencing primers as dashed arrows. Uppercase T denotes cytosines, which have been
converted to uracil during the sodium bisulfite treatment. The CpG sites analyzed are indicated in
bold. (A) ELMO1; (B) ELMO2; (C) ELMO3.
Table 3. Primer sequences and details of the pyrosequencing assays.
Gene Name Primers (5′→3′) Amplicon Size (bp)
ELMO1
Forward primer: TATGAGGGTGAAGGAGTTAATTAGTG
Reverse primer: Biotin-CACCATACATACCTCAAATCTACTATAA
Sequencing primer: AGGGTGAAGGAGTTAATTAGT
107
ELMO2
Forward primer: biotin-GGGGAGGGGTTTTAAGAAGG
Reverse primer: CAAACCTAAACCCAACTCC
Sequencing primer: AACCTAAACCCAACTC
87
ELMO3
Forward primer: GTTGTATGGTTAGGAGTAGTAGTT
Reverse primer: Biotin-CCCCTAAAAACCAAAAAATCCTCCCTTTC
Sequencing primer: GGTTAGGAGTAGTAGTTT
89
4.5. Data Availability
The methylation levels for each of the ELMO gene promoter CpG islands for each of the samples
can be found in the supplementary materials.
4.6. Statistical Analyses
Statistical analyses were performed in SPSS 22.0 for Windows (SPSS Inc., IBM Corp., Armonk, NY,
USA) and in Prism 6 (GraphPad software, San Diego, CA, USA). Goodness-of-fit linear regression was
used to evaluate the possible relations between methylation levels of the individual ELMO genes and
by employing an F test to evaluate if the slopes were significantly different from zero. Comparisons
of clinical characteristics between patients with hypermethylation/hypomethylation and normal
methylation levels for the ELMO gene promoter CpG islands were done using the Fisher’s exact
Int. J. Mol. Sci. 2018, 19, 679 11 of 13
test and the Mann-Whitney U test. Survival probabilities (PFS and OS) were estimated using the
Kaplan-Meier method, while the Cox proportional hazards model was used for univariate analyses of
ELMO methylation level and PFS and OS, respectively, for which the results are presented as hazard
ratios (HR) with 95% confidence interval (CI). Any differences were considered to be statistically
significant when the p value was <0.05.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/3/679/s1.
Acknowledgments: Rigshospitalet, The Novo Nordisk Foundation and the Danish Cancer Society supported
this work.
Author Contributions: Derya Aslan and Lasse Sommer Kristensen carried out the molecular genetic studies.
Signe Regner Michaelsen, Derya Aslan, Thomas Urup and Lasse Sommer Kristensen analyzed the data.
Signe Regner Michaelsen and Hans Skovgaard Poulsen collected the clinical data. Helle Broholm collected
the human material studied. Lasse Sommer Kristensen and Helle Broholm conceived the study. Signe Regner
Michaelsen and Lasse Sommer Kristensen wrote the manuscript. Lasse Sommer Kristensen and Kirsten Grønbæk
contributed reagents and materials. All authors revised the manuscript for important intellectual content and
read and approved the final manuscript.
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results.
References
1. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [CrossRef] [PubMed]
2. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.;
Mason, W.; Mariani, L.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl.
J. Med. 2005, 352, 997–1003. [CrossRef] [PubMed]
3. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.;
Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
4. Giese, A.; Bjerkvig, R.; Berens, M.E.; Westphal, M. Cost of migration: Invasion of malignant gliomas and
implications for treatment. J. Clin. Oncol. 2003, 21, 1624–1636. [CrossRef] [PubMed]
5. Guthrie, B.L.; Laws, E.R., Jr. Supratentorial low-grade gliomas. Neurosurg. Clin. N. Am. 1990, 1, 37–48.
[PubMed]
6. Jarzynka, M.J.; Hu, B.; Hui, K.M.; Bar-Joseph, I.; Gu, W.; Hirose, T.; Haney, L.B.; Ravichandran, K.S.;
Nishikawa, R.; Cheng, S.Y. ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor,
promote human glioma cell invasion. Cancer Res. 2007, 67, 7203–7211. [CrossRef] [PubMed]
7. Kristensen, L.S.; Soes, S.; Hansen, L.L. ELMO3: A direct driver of cancer metastasis? Cell Cycle 2014, 13,
2483–2484. [CrossRef] [PubMed]
8. Soes, S.; Daugaard, I.L.; Sorensen, B.S.; Carus, A.; Mattheisen, M.; Alsner, J.; Overgaard, J.; Hager, H.;
Hansen, L.L.; Kristensen, L.S. Hypomethylation and increased expression of the putative oncogene ELMO3
are associated with lung cancer development and metastases formation. Oncoscience 2014, 1, 367–374.
[CrossRef] [PubMed]
9. Li, H.; Yang, L.; Fu, H.; Yan, J.; Wang, Y.; Guo, H.; Hao, X.; Xu, X.; Jin, T.; Zhang, N. Association
between Galphai2 and ELMO1/Dock180 connects chemokine signalling with Rac activation and metastasis.
Nat. Commun. 2013, 4, 1706. [CrossRef] [PubMed]
10. Abu-Thuraia, A.; Gauthier, R.; Chidiac, R.; Fukui, Y.; Screaton, R.A.; Gratton, J.P.; Cote, J.F. Axl phosphorylates
Elmo scaffold proteins to promote Rac activation and cell invasion. Mol. Cell. Biol. 2015, 35, 76–87. [CrossRef]
[PubMed]
11. Peng, H.Y.; Yu, Q.F.; Shen, W.; Guo, C.M.; Li, Z.; Zhou, X.Y.; Zhou, N.J.; Min, W.P.; Gao, D. Knockdown
of ELMO3 Suppresses Growth, Invasion and Metastasis of Colorectal Cancer. Int. J. Mol. Sci. 2016, 17.
[CrossRef] [PubMed]
12. Gumienny, T.L.; Brugnera, E.; Tosello-Trampont, A.C.; Kinchen, J.M.; Haney, L.B.; Nishiwaki, K.; Walk, S.F.;
Nemergut, M.E.; Macara, I.G.; Francis, R.; et al. CED-12/ELMO, a novel member of the CrkII/Dock180/Rac
pathway, is required for phagocytosis and cell migration. Cell 2001, 107, 27–41. [CrossRef]
Int. J. Mol. Sci. 2018, 19, 679 12 of 13
13. Coskun, M.; Boyd, M.; Olsen, J.; Troelsen, J.T. Control of intestinal promoter activity of the cellular migratory
regulator gene ELMO3 by CDX2 and SP1. J. Cell. Biochem. 2010, 109, 1118–1128. [CrossRef] [PubMed]
14. Ho, E.; Irvine, T.; Vilk, G.J.; Lajoie, G.; Ravichandran, K.S.; D’Souza, S.J.; Dagnino, L. Integrin-linked kinase
interactions with ELMO2 modulate cell polarity. Mol. Biol. Cell 2009, 20, 3033–3043. [CrossRef] [PubMed]
15. Hernandez-Vasquez, M.N.; Adame-Garcia, S.R.; Hamoud, N.; Chidiac, R.; Reyes-Cruz, G.; Gratton, J.P.;
Cote, J.F.; Vazquez-Prado, J. Cell adhesion controlled by adhesion G protein-coupled receptor
GPR124/ADGRA2 is mediated by a protein complex comprising intersectins and Elmo-Dock. J. Biol. Chem.
2017, 292, 12178–12191. [CrossRef] [PubMed]
16. He, Y.; Northey, J.J.; Pelletier, A.; Kos, Z.; Meunier, L.; Haibe-Kains, B.; Mes-Masson, A.M.; Cote, J.F.;
Siegel, P.M.; Lamarche-Vane, N. The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional
co-repressor with Zeb2 in breast cancer. Oncogene 2017, 36, 3490–3503. [CrossRef] [PubMed]
17. Laurin, M.; Cote, J.F. Insights into the biological functions of Dock family guanine nucleotide exchange
factors. Genes Dev. 2014, 28, 533–547. [CrossRef] [PubMed]
18. Kwiatkowska, A.; Didier, S.; Fortin, S.; Chuang, Y.; White, T.; Berens, M.E.; Rushing, E.; Eschbacher, J.;
Tran, N.L.; Chan, A.; et al. The small GTPase RhoG mediates glioblastoma cell invasion. Mol. Cancer 2012,
11, 65. [CrossRef] [PubMed]
19. Laurin, M.; Huber, J.; Pelletier, A.; Houalla, T.; Park, M.; Fukui, Y.; Haibe-Kains, B.; Muller, W.J.; Cote, J.F.
Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast
cancer metastasis. Proc. Natl. Acad. Sci. USA 2013, 110, 7434–7439. [CrossRef] [PubMed]
20. Misek, S.A.; Chen, J.; Schroeder, L.; Rattanasinchai, C.; Sample, A.; Sarkaria, J.N.; Gallo, K.A. EGFR Signals
through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion. Mol. Cancer Res. 2017, 15, 1085–1095.
[CrossRef] [PubMed]
21. Zhang, B.; Shi, L.; Lu, S.; Sun, X.; Liu, Y.; Li, H.; Wang, X.; Zhao, C.; Zhang, H.; Wang, Y. Autocrine IL-8
promotes F-actin polymerization and mediate mesenchymal transition via ELMO1-NF-κB-Snail signaling in
glioma. Cancer Biol. Ther. 2015, 16, 898–911. [CrossRef] [PubMed]
22. Jones, P.A. DNA methylation and cancer. Oncogene 2002, 21, 5358–5360. [CrossRef] [PubMed]
23. Jones, P.A.; Issa, J.P.; Baylin, S. Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 2016, 17, 630–641.
[CrossRef] [PubMed]
24. Dobrovic, A.; Kristensen, L.S. DNA methylation, epimutations and cancer predisposition. Int. J. Biochem.
Cell Biol. 2009, 41, 34–39. [CrossRef] [PubMed]
25. Pirini, F.; Noazin, S.; Jahuira-Arias, M.H.; Rodriguez-Torres, S.; Friess, L.; Michailidi, C.; Cok, J.; Combe, J.;
Vargas, G.; Prado, W.; et al. Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1,
CLIP4 and MSC DNA methylation in endoscopic biopsies. Oncotarget 2017, 8, 38501–38516. [CrossRef]
[PubMed]
26. Mikeska, T.; Bock, C.; Do, H.; Dobrovic, A. DNA methylation biomarkers in cancer: Progress towards clinical
implementation. Expert Rev. Mol. Diagn. 2012, 12, 473–487. [CrossRef] [PubMed]
27. How Kit, A.; Nielsen, H.M.; Tost, J. DNA methylation based biomarkers: Practical considerations and
applications. Biochimie 2012, 94, 2314–2337. [CrossRef] [PubMed]
28. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.;
Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110. [CrossRef]
[PubMed]
29. Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.;
Colman, H.; Soroceanu, L.; et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9, 157–173. [CrossRef]
[PubMed]
30. Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.;
Sulman, E.P.; Bhat, K.P.; et al. Identification of a CpG island methylator phenotype that defines a distinct
subgroup of glioma. Cancer Cell 2010, 17, 510–522. [CrossRef] [PubMed]
31. Sturm, D.; Witt, H.; Hovestadt, V.; Khuong-Quang, D.A.; Jones, D.T.; Konermann, C.; Pfaff, E.; Tonjes, M.;
Sill, M.; Bender, S.; et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological
subgroups of glioblastoma. Cancer Cell 2012, 22, 425–437. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 679 13 of 13
32. Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L.A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A.W.; Lu, C.;
Ward, P.S.; et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature
2012, 483, 479–483. [CrossRef] [PubMed]
33. Kristensen, L.S.; Michaelsen, S.R.; Dyrbye, H.; Aslan, D.; Grunnet, K.; Christensen, I.J.; Poulsen, H.S.;
Gronbaek, K.; Broholm, H. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a
Prognostic Marker in Glioblastoma. J. Neuropathol. Exp. Neurol. 2016, 75, 246–255. [CrossRef] [PubMed]
34. Yagi, K.; Akagi, K.; Hayashi, H.; Nagae, G.; Tsuji, S.; Isagawa, T.; Midorikawa, Y.; Nishimura, Y.; Sakamoto, H.;
Seto, Y.; et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 2010, 16,
21–33. [CrossRef] [PubMed]
35. Slieker, R.C.; Bos, S.D.; Goeman, J.J.; Bovee, J.V.; Talens, R.P.; van der Breggen, R.; Suchiman, H.E.;
Lameijer, E.W.; Putter, H.; van den Akker, E.B.; et al. Identification and systematic annotation of tissue-specific
differentially methylated regions using the Illumina 450k array. Epigenet. Chromatin 2013, 6, 26. [CrossRef]
[PubMed]
36. Lokk, K.; Modhukur, V.; Rajashekar, B.; Martens, K.; Magi, R.; Kolde, R.; Koltsina, M.; Nilsson, T.K.;
Vilo, J.; Salumets, A.; et al. DNA methylome profiling of human tissues identifies global and tissue-specific
methylation patterns. Genome Biol. 2014, 15, r54. [CrossRef] [PubMed]
37. Berchtold, N.C.; Cribbs, D.H.; Coleman, P.D.; Rogers, J.; Head, E.; Kim, R.; Beach, T.; Miller, C.; Troncoso, J.;
Trojanowski, J.Q.; et al. Gene expression changes in the course of normal brain aging are sexually dimorphic.
Proc. Natl. Acad. Sci. USA 2008, 105, 15605–15610. [CrossRef] [PubMed]
38. Everhard, S.; Tost, J.; El Abdalaoui, H.; Criniere, E.; Busato, F.; Marie, Y.; Gut, I.G.; Sanson, M.; Mokhtari, K.;
Laigle-Donadey, F.; et al. Identification of regions correlating MGMT promoter methylation and gene
expression in glioblastomas. Neuro-Oncology 2009, 11, 348–356. [CrossRef] [PubMed]
39. Lim, A.M.; Candiloro, I.L.; Wong, N.; Collins, M.; Do, H.; Takano, E.A.; Angel, C.; Young, R.J.; Corry, J.;
Wiesenfeld, D.; et al. Quantitative methodology is critical for assessing DNA methylation and impacts on
correlation with patient outcome. Clin. Epigenet. 2014, 6, 22. [CrossRef] [PubMed]
40. Wedge, E.; Hansen, J.W.; Garde, C.; Asmar, F.; Tholstrup, D.; Kristensen, S.S.; Munch-Petersen, H.D.;
Ralfkiaer, E.; Brown, P.; Gronbaek, K.; et al. Global hypomethylation is an independent prognostic factor in
diffuse large B cell lymphoma. Am. J. Hematol. 2017, 92, 689–694. [CrossRef] [PubMed]
41. Tost, J.; Gut, I.G. DNA methylation analysis by pyrosequencing. Nat. Protoc. 2007, 2, 2265–2275. [CrossRef]
[PubMed]
42. Fan, W.; Yang, H.; Xue, H.; Sun, Y.; Zhang, J. ELMO3 is a novel biomarker for diagnosis and prognosis of
non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2015, 8, 5503–5508. [PubMed]
43. Kadletz, L.; Heiduschka, G.; Wiebringhaus, R.; Gurnhofer, E.; Kotowski, U.; Haymerle, G.; Brunner, M.;
Barry, C.; Kenner, L. ELMO3 expression indicates a poor prognosis in head and neck squamous cell
carcinoma—A short report. Cell. Oncol. 2017, 40, 193–198. [CrossRef] [PubMed]
44. Haymerle, G.; Kadletz, L.; Wiebringhaus, R.; Golabi, B.; Mildner, M.; Thurnher, D.; Heiduschka, G. ELMO3
predicts poor outcome in T1 laryngeal cancer. Clin. Otolaryngol. 2017. [CrossRef] [PubMed]
45. Michaelsen, S.R.; Christensen, I.J.; Grunnet, K.; Stockhausen, M.T.; Broholm, H.; Kosteljanetz, M.;
Poulsen, H.S. Clinical variables serve as prognostic factors in a model for survival from glioblastoma
multiforme: An observational study of a cohort of consecutive non-selected patients from a single institution.
BMC Cancer 2013, 13, 402. [CrossRef] [PubMed]
46. Mikeska, T.; Felsberg, J.; Hewitt, C.A.; Dobrovic, A. Analysing DNA methylation using bisulphite
pyrosequencing. Methods Mol. Biol. 2011, 791, 33–53. [CrossRef] [PubMed]
47. Kristensen, L.S.; Hansen, J.W.; Kristensen, S.S.; Tholstrup, D.; Harslof, L.B.; Pedersen, O.B.;
De Nully Brown, P.; Gronbaek, K. Aberrant methylation of cell-free circulating DNA in plasma predicts poor
outcome in diffuse large B cell lymphoma. Clin. Epigenet. 2016, 8, 95. [CrossRef] [PubMed]
48. Kristensen, L.S.; Treppendahl, M.B.; Gronbaek, K. Analysis of epigenetic modifications of DNA in human
cells. Curr. Protoc. Human Genet. 2013. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
